These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669 [TBL] [Abstract][Full Text] [Related]
29. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Duensing A; Medeiros F; McConarty B; Joseph NE; Panigrahy D; Singer S; Fletcher CD; Demetri GD; Fletcher JA Oncogene; 2004 May; 23(22):3999-4006. PubMed ID: 15007386 [TBL] [Abstract][Full Text] [Related]
30. High CD133 expression levels in gastrointestinal stromal tumors. Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307 [TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Matei D; Chang DD; Jeng MH Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091 [TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy of gastrointestinal stromal tumours. Eisenberg BL; von Mehren M Expert Opin Pharmacother; 2003 Jun; 4(6):869-74. PubMed ID: 12783584 [TBL] [Abstract][Full Text] [Related]
33. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
34. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. Ohashi A; Kinoshita K; Isozaki K; Nishida T; Shinomura Y; Kitamura Y; Hirota S Int J Cancer; 2004 Sep; 111(3):317-21. PubMed ID: 15221957 [TBL] [Abstract][Full Text] [Related]
35. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568 [TBL] [Abstract][Full Text] [Related]
37. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Bauer S; Duensing A; Demetri GD; Fletcher JA Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049 [TBL] [Abstract][Full Text] [Related]
38. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976 [TBL] [Abstract][Full Text] [Related]
39. Recent advances in the management of gastrointestinal stromal tumors. von Mehren M Curr Oncol Rep; 2003 Jul; 5(4):288-94. PubMed ID: 12781070 [TBL] [Abstract][Full Text] [Related]
40. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. de Jong FA; Verweij J Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]